Stroke prevention in atrial fibrillation: Current anticoagulation management and future directions

Article Type
Article
Changed
Tue, 09/25/2018 - 11:06
Display Headline
Stroke prevention in atrial fibrillation: Current anticoagulation management and future directions
Author(s)
Benjamin T. Fitzgerald, MBBS
Steven L. Cohn, MD
Allan L. Klein, MD, FRCP(C), FACC, FAHA, FASE
Article PDF
content_72_Suppl_1_SI-24.pdf
Author and Disclosure Information

Benjamin T. Fitzgerald, MBBS
Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio

Steven L. Cohn, MD
Division of General Internal Medicine, State University of New York Downstate, Brooklyn, NY

Allan L. Klein, MD
Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio

Correspondence: Allan L. Klein, MD, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk F15, Cleveland, OH 44195; kleina@ccf.org

Dr. Fitzgerald has indicated that he has nothing to disclose.

Dr. Cohn is on the speakers' bureaus of AstraZeneca, Bristol-Myers Squib, and Sanofi-Aventis.

Dr. Klein has received grant/research support from Sanofi-Aventis.

Publications
Cleveland Clinic Journal of Medicine
Page Number
S24-S30
Author(s)
Benjamin T. Fitzgerald, MBBS
Steven L. Cohn, MD
Allan L. Klein, MD, FRCP(C), FACC, FAHA, FASE
Author(s)
Benjamin T. Fitzgerald, MBBS
Steven L. Cohn, MD
Allan L. Klein, MD, FRCP(C), FACC, FAHA, FASE
Author and Disclosure Information

Benjamin T. Fitzgerald, MBBS
Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio

Steven L. Cohn, MD
Division of General Internal Medicine, State University of New York Downstate, Brooklyn, NY

Allan L. Klein, MD
Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio

Correspondence: Allan L. Klein, MD, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk F15, Cleveland, OH 44195; kleina@ccf.org

Dr. Fitzgerald has indicated that he has nothing to disclose.

Dr. Cohn is on the speakers' bureaus of AstraZeneca, Bristol-Myers Squib, and Sanofi-Aventis.

Dr. Klein has received grant/research support from Sanofi-Aventis.

Author and Disclosure Information

Benjamin T. Fitzgerald, MBBS
Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio

Steven L. Cohn, MD
Division of General Internal Medicine, State University of New York Downstate, Brooklyn, NY

Allan L. Klein, MD
Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio

Correspondence: Allan L. Klein, MD, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk F15, Cleveland, OH 44195; kleina@ccf.org

Dr. Fitzgerald has indicated that he has nothing to disclose.

Dr. Cohn is on the speakers' bureaus of AstraZeneca, Bristol-Myers Squib, and Sanofi-Aventis.

Dr. Klein has received grant/research support from Sanofi-Aventis.

Article PDF
content_72_Suppl_1_SI-24.pdf
Article PDF
content_72_Suppl_1_SI-24.pdf
Page Number
S24-S30
Page Number
S24-S30
Publications
Cleveland Clinic Journal of Medicine
Publications
Cleveland Clinic Journal of Medicine
Article Type
Article
Display Headline
Stroke prevention in atrial fibrillation: Current anticoagulation management and future directions
Display Headline
Stroke prevention in atrial fibrillation: Current anticoagulation management and future directions
Citation Override
Cleveland Clinic Journal of Medicine 2005 April;72(suppl 1):S24-S30
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media
Subscribe to Benjamin T. Fitzgerald, MBBS